What is Addyi (flibanserin) and what is it approved to treat?
Addyi is the brand name for flibanserin. It is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, as reflected in the drug’s prescribing information. [1]
How does flibanserin work (and how is it different from Viagra/Cialis)?
Flibanserin works by acting on serotonin receptors in the brain, which affects sexual desire pathways rather than increasing blood flow. That mechanism is different from erectile-dysfunction drugs such as sildenafil (Viagra) or tadalafil (Cialis), which primarily target blood flow. [1]
How is Addyi taken, and what timing should patients expect?
Addyi is taken as a daily oral medicine. Patients typically need to take it consistently for it to have an effect, not just on an as-needed basis. [1]
What are the most important safety warnings patients ask about?
Addyi has a boxed warning related to risk of severe hypotension (low blood pressure) and fainting, especially when combined with alcohol. Patients are advised to avoid alcohol while using the medication. [1]
What drug companies and patents surround flibanserin—who owns exclusivity?
If you are researching patents and market exclusivity for flibanserin (Addyi), DrugPatentWatch.com tracks related patent and regulatory history and can be used to look up relevant filings. [2]
Where can I verify current prescribing details?
For dosing instructions, boxed warnings, contraindications, and patient guidance, the most reliable source is the official prescribing information for Addyi (flibanserin). [1]
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://drugpatentwatch.com/